Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration
Primary Purpose
End-stage Renal Disease
Status
Completed
Phase
Phase 4
Locations
Thailand
Study Type
Interventional
Intervention
Acetate-free dialysis solution
Sponsored by
About this trial
This is an interventional treatment trial for End-stage Renal Disease
Eligibility Criteria
Inclusion Criteria:
- End-stage renal disease patients with age over 20 years and stable clinical status
- Dialytic age > 6 months
- Maintenance hemodialysis with online-hemodiafiltration mode at King Chulalongkorn Memorial Hospital
- Use arteriovenous fistula or arteriovenous graft as vascular access for hemodialysis
- No vascular access recirculation
- No liver impairment
- No severe, intractable metabolic acidosis or alkalosis (HCO3 <15, >30)
- No pre-existing severe, intractable hypocalcemia (Ca < 7.5) or clinical of hypocalcemia
Exclusion Criteria:
- On hemodialysis via tunnel catheter
- Vascular access recirculation
- Liver dysfunction
- Severe, intractable metabolic acidosis or alkalosis (HCO3 <15, >30)
- Pre-existing severe, intractable hypocalcemia (Ca < 7.5) or clinical of hypocalcemia
- Acute or recent myocardial ischemia or congestive heart failure (within 1 months)
- Threatening arrhythmia (VT, VF, sustained SVT, AF with rapid ventricular response)
- Patients affected by acute or chronic infections, malignant tumor
Sites / Locations
- Faculty of Medicine, Chulalongkorn University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Acetate-free solution first
Acetate-based solution first
Arm Description
Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
Outcomes
Primary Outcome Measures
cardiac index
cardiac index and cardiac output was measured by ultrasound dilution technique
Cardiac output
cardiac index and cardiac output was measured by ultrasound dilution technique
Secondary Outcome Measures
blood pressure
peripheral vascular resistance
Patients' symptoms
dizziness, palpitation, nausea, cramp, numbness
Full Information
NCT ID
NCT01778283
First Posted
December 20, 2012
Last Updated
February 12, 2013
Sponsor
Chulalongkorn University
1. Study Identification
Unique Protocol Identification Number
NCT01778283
Brief Title
Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration
Official Title
Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration
Study Type
Interventional
2. Study Status
Record Verification Date
February 2013
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chulalongkorn University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to detemine whether effect of Acetate-free solution on cardiac index and cardiac output measured by saline dilution techniques compares with Acetate-based solution in online-hemodiafiltration
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End-stage Renal Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
22 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Acetate-free solution first
Arm Type
Experimental
Arm Description
Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
Arm Title
Acetate-based solution first
Arm Type
Active Comparator
Arm Description
Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
Intervention Type
Biological
Intervention Name(s)
Acetate-free dialysis solution
Intervention Description
the hemodialysis solution that does not contain acetate as buffer
Primary Outcome Measure Information:
Title
cardiac index
Description
cardiac index and cardiac output was measured by ultrasound dilution technique
Time Frame
6 months
Title
Cardiac output
Description
cardiac index and cardiac output was measured by ultrasound dilution technique
Time Frame
6 months
Secondary Outcome Measure Information:
Title
blood pressure
Time Frame
6 months
Title
peripheral vascular resistance
Time Frame
6 moths
Title
Patients' symptoms
Description
dizziness, palpitation, nausea, cramp, numbness
Time Frame
6 months
Other Pre-specified Outcome Measures:
Title
cardiac marker, serum electrolyte, inflammatory marker
Description
BUN, creatinine, serum sodium, serum potassium, serum bicarbonate, serum calcium, ionized calcium, serum magnesium, serum osmol, troponin T, NT-proBNP, CKMB, hs-CRP
Time Frame
January 2013
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
End-stage renal disease patients with age over 20 years and stable clinical status
Dialytic age > 6 months
Maintenance hemodialysis with online-hemodiafiltration mode at King Chulalongkorn Memorial Hospital
Use arteriovenous fistula or arteriovenous graft as vascular access for hemodialysis
No vascular access recirculation
No liver impairment
No severe, intractable metabolic acidosis or alkalosis (HCO3 <15, >30)
No pre-existing severe, intractable hypocalcemia (Ca < 7.5) or clinical of hypocalcemia
Exclusion Criteria:
On hemodialysis via tunnel catheter
Vascular access recirculation
Liver dysfunction
Severe, intractable metabolic acidosis or alkalosis (HCO3 <15, >30)
Pre-existing severe, intractable hypocalcemia (Ca < 7.5) or clinical of hypocalcemia
Acute or recent myocardial ischemia or congestive heart failure (within 1 months)
Threatening arrhythmia (VT, VF, sustained SVT, AF with rapid ventricular response)
Patients affected by acute or chronic infections, malignant tumor
Facility Information:
Facility Name
Faculty of Medicine, Chulalongkorn University
City
Bangkok
ZIP/Postal Code
10330
Country
Thailand
12. IPD Sharing Statement
Learn more about this trial
Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration
We'll reach out to this number within 24 hrs